Tolerability and efficacy of second-line antifibrotics in patients with idiopathic pulmonary fibrosis.
Pulmonary pharmacology & therapeutics, vol.71, pp.102099, 2021 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 71
- Publication Date: 2021
- Doi Number: 10.1016/j.pupt.2021.102099
- Journal Name: Pulmonary pharmacology & therapeutics
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, Chemical Abstracts Core, EMBASE, MEDLINE
- Page Numbers: pp.102099
- Keywords: IPF, Nintedanib, Pirfenidone, Switch, ACUTE EXACERBATION, PIRFENIDONE, NINTEDANIB, SAFETY
- Bursa Uludag University Affiliated: Yes
Abstract
Background: The antifibrotic drugs nintedanib and pirfenidone reduce disease progression in idiopathic pulmonary fibrosis (IPF) and have also shown to improve survival. Switching first-line antifibrotic drug may required in IPF due to disease progression or intolerable adverse effects. The aim of this study was to assess the safety and efficacy of second-line antifibrotic treatment in patients with IPF.